Bacterial Culture, Cystic Fibrosis with Antimicrobial Susceptibilities, Varies
Use
This test is useful for detecting disease-causing aerobic bacteria in specimens from patients with cystic fibrosis. It aids in determining the in vitro antimicrobial susceptibility of potentially pathogenic aerobic bacteria, which is crucial for appropriate treatment. The life expectancy of patients with CF has increased due to improved lung disease management, yet 75% to 85% of deaths in CF patients are due to chronic lung infections. Early and accurate detection of pathogens can lead to better management and outcomes.
Special Instructions
Specimen must be received in laboratory within 48 hours of collection at refrigerated temperature. Specimens received frozen will be rejected. Specimen source is required for this test. Antimicrobial agent appropriate to the organism and specimen source will be tested according to Mayo Clinic's practice.
Limitations
Some bacterial agents like Mycobacteria, Legionella species, and Mycoplasma pneumoniae are not detected by this assay and require special procedures. A negative test result does not rule out all causes of infectious lung disease. Antimicrobial susceptibilities do not guarantee clinical response. Overgrowth of oropharyngeal microbiota can occur if the specimen is not handled properly.
FDA ApprovedNew York Approved
Methodology
Culture-based
Biomarkers
LOINC Codes
- 44798-7
- 44798-7
Result Turnaround Time
4-12 days
Related Documents
For more information, please review the documents below
Specimen
Sputum
Volume
Entire collection
Minimum Volume
Not provided
Container
Sterile container
Collection Instructions
Have the patient brush their teeth or gargle with water immediately before specimen collection to reduce oropharyngeal bacteria.
Causes for Rejection
Dry swab
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 48 hours |